World-first lung cancer vaccine trials launched across seven countries
Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8 million deaths every year. Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them from ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer, the most common form of the disease. The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the U.K., U.S., Germany, Hungary, Poland, Spain, and Turkey.
World-first lung cancer vaccine trials launched across seven countries Read more